TABLE 1.
Variables of study in patients under intracardiac device implantation in the first peak of COVID‐19 pandemic
| Variables | COVID‐19 pandemic period | Control period | Variation % | P‐value | |
|---|---|---|---|---|---|
| Total number of intracardiac device implantation | 10 | 48 | −80 | ‐ | |
| Gender (male/female) | 4/6 | 34/14 | ‐ | 0.06 | |
| Age (mean ±SD) (years) | 61.22 ± 14.13 | 57.22 ± 17.50 | ‐ | 0.52 | |
| Indication for PPM implantation | AF with bradycardia | 0 | 1 (2.1%) | −100 |
0.03 |
| SAN diseases | 1 (10%) | 1 (2.1%) | 0 | ||
| AVN diseases | 6 (60%) | 7 (14.6%) | −14 | ||
| Indication for ICD/CRT implantation | LV dysfunction | 1 (10%) | 9 (18.8%) | −89 | |
| ERI ICD/CRT | 1 (10%) | 9 (18.8%) | −89 | ||
| ICMP, DCM, HCM | 1 (10%) | 17 (35.4%) | −94 | ||
| Other indications | High threshold RV lead/RV lead dislodgment | 0 | 4 (8.3%) | −100 | |
AF, atrial fibrillation; AVN, atrioventricular node, CHB, complete heart block, CRT, cardiac resynchronization therapy, DCM, dilated cardiomyopathy, ERI, elective replacement indicator, HCM, hypertrophic cardiomyopathy, ICD, implantable cardioverter defibrillators, ICMP, ischemic cardiomyopathy, LV, left ventricle, PPM, permanent pacemaker, RV, right ventricle, SAN, sinoatrial node.